The bioequivalence of oral and intravenous ofloxacin was investigated after the administration of multiple doses of 400 mg every 12 h to 20 healthy male volunteers in a randomized, crossover, open-label study. Ofloxacin concentrations in plasma were evaluated after 4 days of oral or intravenous (1-h infusion) dosing with a 3-day wash-out period between regimens. As expected, delivery to the systemic circulation took slightly longer after the oral dosing (time to maximum concentration of drug in serum of 1.7 h) relative to the 1-h intravenous infusion, but the systemic availabilities of ofloxacin by the two routes of administration were equivalent (area under the concentration-time curve from 0 to 12 h ratio of 95%). Since previous studies have not demonstrated any change in the bioavailability of ofloxacin in infectious disease patients, this study supports the interchangeability of these dosing regimens.
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Ofloxacin is a synthetic carboxyquinolone antimicrobial agent with potent broad-spectrum bactericidal activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria (8) . Ofloxacin has been available in the United States as 200-, 300-, and 400-mg tablets since January 1991 and as a 200-, 300-, or 400-mg intravenous (i.v.) formulation since March 1992.
Previous studies have demonstrated that ofloxacin is rapidly absorbed from the gastrointestinal tract after oral (p.o.) administration and that it is nearly 100% bioavailable after a single dose (8) , but no study had yet defined the absolute bioavailability of ofloxacin at steady-state levels. Thus, the present study was conducted to investigate the bioequivalence of the marketed p.o. and i.v. formulations when administered every 12 h (ql2h).
MATERIALS AND METHODS
Subjects. Twenty healthy male subjects ranging in age from 18 to 41 years (mean, 26 years) and weighing from 134 (ca. 61 kg) to 221 (ca. 100 kg) lb (mean, 169 lb [ca. 77 kg]) were enrolled in the study. The subjects were judged healthy on the basis of the results of the prestudy values of vital signs (pulse, oral temperature, and sitting blood pressure), laboratory profiles (hematology profile, blood chemistry, and urinalysis), urine toxicology screen, and human immunodeficiency virus screen. None of the subjects had a previous history of allergy to 2 h of a dose. For the morning doses, subjects fasted from at least midnight of the previous day. On days 5 and 13, food was not consumed after the prior evening meal until 2 h after the morning dose. Venous blood samples (5 ml) were drawn from each volunteer immediately prior to each dose on days 1, 3, 4, 9, 11, and 12. On days 5 and 13, blood samples were drawn immediately prior to dosing and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 16, and 24 h after dosing began.
Analytical procedures. Plasma samples were analyzed for ofloxacin by a sensitive and specific high-pressure liquid chromatographic method previously described (3) . After extraction at pH 7 with dichloromethane, the extract was injected onto a C18 ,uBondapak column (25 cm by 4.6 mm [inner diameter]; Waters Associates Inc., Milford, Mass.). The mobile phase consisted of 1.74 g of potassium dihydrogen phosphate and 20 mg of 1-hexanesulfonic sodium salt (Eastman Kodak Co., Rochester, N.Y.) dissolved in 650 ml of distilled water, combined with 350 ml of methanol, and adjusted to pH 3 with phosphoric acid. The imidazolic derivative of ofloxacin (Daiichi Seiyaku) was used as the internal standard. Detection was done with a UV detector at 313 nm. The limit of quantitation was 0.01 mg/liter, and the extraction efficiency was more than 75%. The assay was linear over the concentration range of 0.025 to 9 mg/liter. The intra-and interday coefficients of variation ranged from 3 to 6% over the standard curve concentration range of 0.025 to 9 mg/liter. Pharmacokinetics. Because of a technical malfunction, one data set was lost during sample analysis, hence the pharmacokinetic and statistical analyses were based on a total of 19 subjects. Mean steady-state plasma ofloxacin concentrations obtained after p.o. or i.v. administration are plotted in Fig. 1 . As shown in Fig. 1 The pharmacokinetic results and concentrations in plasma were comparable to those previously observed after administration of similar dosing regimens, i.v. or p.o., to volunteers or patients with normal renal function (1, 5) . Previous studies have not shown any change in the bioavailability of ofloxacin in infectious disease patients versus normal volunteers (1, 2, 6, 7, 11, 13, 14) . The bioavailability of ofloxacin has been previously investigated after administration of single doses (5, 15) , but to our knowledge this is the first study that has investigated it under steady-state conditions. As has been previously shown after single doses, the 400-mg tablet showed complete p.o. bioavailability. Since the absorption of ofloxacin from the tablet formulation required more time than the 1-h i.v. infusion period, modest but statistically significant differences in Tm. and Cm. values were observed between these forms of administration. This phenomenon was also observed in the single-dose studies (5, 15) . As expected, these slight differences in absorption rate 37, 1993 on September 20, 2017 by guest http://aac.asm.org/ Downloaded from mg ql2h, but the excellent dose proportionality previously exhibited by ofloxacin (3, 4) suggests that the current findings can be extrapolated to the 200-and 300-mg once-a-day or ql2h regimens.
